UnknownPhase 3NCT03243461
International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Göttingen
- Principal Investigator
- Christof Kramm, Prof., MDUniversity of Göttingen
- Intervention
- Temozolomide + Valproic Acid(drug)
- Enrollment
- 167 enrolled
- Eligibility
- 3-17 years · All sexes
- Timeline
- 2018 – 2023
Study locations (30)
- Universitätsklinik RWTH Aachen, Aachen, Germany
- Klinikum Augsburg, Augsburg, Germany
- Charité Universitätsmedizin Berlin, Berlin, Germany
- HELIOS Klinikum Berlin Buch, Berlin, Germany
- Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany
- Universitätsklinikum Bonn, Bonn, Germany
- Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany
- Klinikum Bremen-Mitte gGmbH, Bremen, Germany
- Kliniken der Stadt Köln gGmbH, Cologne, Germany
- Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, Germany
- Klinikum Dortmund gGmbH, Dortmund, Germany
- Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
- Sana Kliniken Duisburg GmbH - Wedau Kliniken, Duisburg, Germany
- HELIOS Klinikum Erfurt GmbH, Erfurt, Germany
- Universitätsklinikum Erlangen, Erlangen, Germany
- +15 more locations on ClinicalTrials.gov
Collaborators
Deutsche Kinderkrebsstiftung · Hannover Medical School
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03243461 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah